18th Annual Hypertension, Diabetes and Dyslipidemia Conference (endorsed by the American Society of Hypertension)

Gaps in the level of Hemoglobin A1C, BP, and LDL-Cholesterol reduction continue to occur in high-risk individuals with Type 2 diabetes, Hypertension, and Dyslipidemia, respectively. Recent results from the ACCORD, VADT, and ADVANCE studies suggest the benefits on reducing macrovascular disease events are unclear and, in fact, caution should be exercised when reducing Hemoglobin A1C in those with long standing Type 2 diabetes to a goal of < 6% when compared to a goal between 7 and 7.9%. In addition, controversy continues from recent guidelines on the level of LDL-cholesterol and BP reduction that can be and should be achieved. This conference will address these and other issues confronting the clinician who treats patients with diabetes, hypertension, and dyslipidemia. The participant will learn the most current information on these issues and will be able to transport these clinical principles back to their every day practice to improve patient care. OBJECTIVES At the completion of this activity, participants should be better prepared to: • Discuss goals, medications and controversies surrounding management of patients with Diabetes, Hypertension and Dyslipidemia; • Describe appropriate treatment plans for these individuals; and • Apply new learning to improve health outcomes involving patients with Diabetes, Hypertension, and Dyslipidemia.

del 27 al 29 de junio de 2014 | Charleston (Estados Unidos)

Sede

Doubletree by Hilton

181 Church Street Charleston SC 29401

Charleston (Estados Unidos)

cargando...

Secretaría del Congreso

¿Necesita contactar? Identifíquese.

correo electrónico

contraseña

  ¿olvidó su password?

Aún no está registrado?, regístrese

Organizador

Continuing Education Company Inc

Especialidades relacionadas